Journal
THROMBOSIS RESEARCH
Volume 169, Issue -, Pages 135-139Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.thromres.2018.07.023
Keywords
-
Categories
Ask authors/readers for more resources
Background: Anticoagulation with unfractionated heparin (UFH) or low molecular weight heparin (LMWH) is the mainstay for the treatment of patients with acute cerebral vein thrombosis (CVT) with or without intracranial hemorrhage (ICH). Aim: We conducted a systematic review and meta-analysis to determine the efficacy and safety of LMWH compared to UFH for the treatment of acute CVT. Methods: An electronic search of MEDLINE, Pubmed, CENTRAL and Google Scholar was performed. Randomized controlled trials (RCT) reporting on the efficacy and safety of anticoagulation for acute treatment of CVT were included. Outcomes of interest included mortality, disability, new ICH and pulmonary embolism (PE). Results: Overall, 4 RCTs were included in the meta-analysis. Two trials compared anticoagulation (UFH (N=1) and LMWH (N=1)) to placebo. The use of anticoagulation therapy was associated with an odd ratio (OR) for mortality and disability of 0.31 (95% confidence interval (CI) 0.07 to 1.45; p=0.14) and 0.3 (95% CI 0.09 to 1.01; p=0.05), respectively. Three new ICHs were observed among patients receiving placebo and no patient had a PE complication. The other two trials compared LMWH to UFH. LMWH was associated with an OR for mortality and disability of 0.21 (95% CI 0.02 to 2.44, p=0.21) and 0.5 (95% CI 0.11 to 2.23; p=0.36), respectively. There were no new events of ICH or PE. Conclusion: LMWH seems to be safe and effective for the management of acute CVT.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available